Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02914483 · ClinicalTrials.gov registry record · NA
Women's Heart Attack Research Program: Stress Ancillary Study
A NA study of Myocardial Infarction, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- NA
- Development phase
- 200
- Enrollment target
- 14
- Study locations
NCT02914483: Recruiting NA study of Myocardial Infarction, sponsored by NYU Langone Health.
NCT02914483 is a NA study of Myocardial Infarction that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 200 participants, below the 4,679-participant average among 64 other Myocardial Infarction trials with a reported enrollment target (96% lower). The trial reports 14 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02914483, a NA study of Myocardial Infarction, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
- 14
- Study locations
Study Summary
The Women's HARP study is a multi-center study focusing on women with clinical presentation of myocardial infarction (MI). Women will complete stress questionnaires following presentation to the medical center with elevated cardiac enzymes and abnormal electrocardiograms (ECGs). 2 months following MI, participants will be screened for the Stress Ancillary Study and enrolled if an elevated level of perceived stress is reported. After completing baseline assessments, participants will be randomized to Enhanced Usual Care (EUC) or stress management for 8 weeks. Participants will be followed for 6 months.
Primary Outcome
6-month change in perceived stress as measured by Perceived Stress Scale (PSS-10)
Conditions Studied
Interventions
- BEHAVIORAL Enhanced Usual Care
- BEHAVIORAL Stress Management
- DIAGNOSTIC_TEST Actigraph
Study Locations (14)
New York
- NYU Winthrop - Mineola
- NYU Langone Medical Center - New York
- Columbia University Medical Center - New York
Pennsylvania
- St. Luke's University Health Network - Bethlehem
- University of Pittsburgh Medical Center - Pittsburgh
California
- Cedars-Sinai Medical Center - Los Angeles
Florida
- Univeristy of Florida - Gainesville
Georgia
- Emory University - Atlanta
Maryland
- Johns Hopkins Medical Center - Baltimore
New Hampshire
- Dartmouth-Hitchcock - Lebanon
Ohio
- Ohio State University Medical Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2016-08-01 |
| Est. Completion | 2026-06-30 |
| Phase | NA |
What NCT02914483 shows while recruiting
NCT02914483 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 4,679-participant average among 64 other Myocardial Infarction trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Myocardial Infarction appearing as the primary indexed condition, and to 3 interventions - of which Enhanced Usual Care is the first listed.
NCT02914483 lists 14 locations in 11 states (New York, Pennsylvania, California).
Frequently Asked Questions
What is clinical trial NCT02914483 about?
NCT02914483 is a clinical study titled "Women's Heart Attack Research Program: Stress Ancillary Study". The Women's HARP study is a multi-center study focusing on women with clinical presentation of myocardial infarction (MI). Women will complete stress questionnaires following presentation to the medical center with elevated cardiac enzymes and abnormal electrocardiograms (ECGs). 2 months following M...
What is the current status of trial NCT02914483?
This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2016-08-01. Estimated completion is 2026-06-30.
What conditions does trial NCT02914483 study?
This clinical trial studies the following conditions: Myocardial Infarction.
What interventions are being tested in trial NCT02914483?
The interventions under investigation include: Enhanced Usual Care (BEHAVIORAL), Stress Management (BEHAVIORAL), Actigraph (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT02914483?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02914483 being conducted?
This trial has 14 study locations across California, Florida, Georgia, Maryland, New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myocardial Infarction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02914483's enrollment target sits among peer trials
200 42nd of 64 higher than 23 of 64 other Myocardial Infarction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myocardial Infarction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation
RECRUITING · NA
-
Cardiac Radioablation for VT
RECRUITING · NA
-
Examination of the Impact of CalmiGo's Stress Management Device on Vascular Heath and Cardiovascular Disease Risk.
RECRUITING · NA
-
Reducing Blood Pressure in Patients With High Cardiovascular Risk
RECRUITING · NA
-
Influence of Pulse Electromagnetic Field Therapy on Myocardial Ischemia
RECRUITING · NA
-
Smartphone Twelve-Lead ECG Utility In ST-Elevation Myocardial Infarction II
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI